Core Viewpoint - Nanjing Pharmaceutical plans to acquire assets from Future Pharmaceutical for up to 480 million yuan, enhancing its "healthcare" strategy and product pipeline [1][2] Group 1: Acquisition Details - The acquisition involves cash payment for a set of assets, including three injectable products focused on trace element supplementation [1] - The three products are already listed and covered by national medical insurance, catering to all age groups from infants to adults [1] - The asset group includes comprehensive resources from R&D to sales, including technical data, trademarks, patents, customer information, and drug approvals [1] Group 2: Strategic Implications - The acquisition is expected to provide immediate revenue and profit contributions due to the established market presence of the injectable products [2] - It will enhance the company's ability to sustain operations and improve overall profitability [2] - The deal aligns with the company's long-term strategy to enrich its product pipeline and strengthen its position in the "nutrition support" sector, complementing its existing product layout [2] - This strategic move is seen as a significant step towards optimizing product structure and enhancing competitive strength in the market [2]